Exploiting mitochondrial and metabolic homeostasis as a vulnerability in NF1 deficient cells

Robert J. Allaway, Matthew Wood, Sondra L. Downey, Stephanie J. Bouley, Nicole A. Traphagen, Jason D. Wells, Jaya Batra, Sir Norman Melancon, Carol Ringelberg, William Seibel, Nancy Ratner, Nancy Yolanda Sanchez

Research output: Contribution to journalArticle

Abstract

Neurofibromatosis type 1 is a disease caused by mutation of neurofibromin 1 (NF1), loss of which results in hyperactive Ras signaling and a concomitant increase in cell proliferation and survival. Patients with neurofibromatosis type 1 frequently develop tumors such as plexiform neurofibromas and malignant peripheral nerve sheath tumors. Mutation of NF1 or loss of the NF1 protein is also observed in glioblastoma, lung adenocarcinoma, and ovarian cancer among other sporadic cancers. A therapy that selectively targets NF1 deficient tumors would substantially advance our ability to treat these malignancies. To address the need for these therapeutics, we developed and conducted a synthetic lethality screen to discover molecules that target yeast lacking the homolog of NF1, IRA2. One of the lead candidates that was observed to be synthetic lethal with ira2Δ yeast is Y100. Here, we describe the mechanisms by which Y100 targets ira2Δ yeast and NF1-deficient tumor cells. Y100 treatment disrupted proteostasis, metabolic homeostasis, and induced the formation of mitochondrial superoxide in NF1-deficient cancer cells. Previous studies also indicate that NF1/Ras-dysregulated tumors may be sensitive to modulators of oxidative and ER stress. We hypothesize that the use of Y100 and molecules with related mechanisms of action represent a feasible therapeutic strategy for targeting NF1 deficient cells.

Original languageEnglish (US)
Pages (from-to)15860-15875
Number of pages16
JournalOncotarget
Volume9
Issue number22
DOIs
StatePublished - Jan 1 2018
Externally publishedYes

Fingerprint

Neurofibromin 1
Homeostasis
Neoplasms
Neurofibromatosis 1
Yeasts
Plexiform Neurofibroma
Mutation
Neurilemmoma
Therapeutics
Glioblastoma
Superoxides
Ovarian Neoplasms
Lung Neoplasms
Cell Survival
Oxidative Stress
Cell Proliferation

Keywords

  • Mitochondria
  • Neurofibromin 1
  • Proteostasis
  • RAS
  • Synthetic lethal

ASJC Scopus subject areas

  • Oncology

Cite this

Allaway, R. J., Wood, M., Downey, S. L., Bouley, S. J., Traphagen, N. A., Wells, J. D., ... Sanchez, N. Y. (2018). Exploiting mitochondrial and metabolic homeostasis as a vulnerability in NF1 deficient cells. Oncotarget, 9(22), 15860-15875. https://doi.org/10.18632/oncotarget.19335

Exploiting mitochondrial and metabolic homeostasis as a vulnerability in NF1 deficient cells. / Allaway, Robert J.; Wood, Matthew; Downey, Sondra L.; Bouley, Stephanie J.; Traphagen, Nicole A.; Wells, Jason D.; Batra, Jaya; Melancon, Sir Norman; Ringelberg, Carol; Seibel, William; Ratner, Nancy; Sanchez, Nancy Yolanda.

In: Oncotarget, Vol. 9, No. 22, 01.01.2018, p. 15860-15875.

Research output: Contribution to journalArticle

Allaway, RJ, Wood, M, Downey, SL, Bouley, SJ, Traphagen, NA, Wells, JD, Batra, J, Melancon, SN, Ringelberg, C, Seibel, W, Ratner, N & Sanchez, NY 2018, 'Exploiting mitochondrial and metabolic homeostasis as a vulnerability in NF1 deficient cells', Oncotarget, vol. 9, no. 22, pp. 15860-15875. https://doi.org/10.18632/oncotarget.19335
Allaway, Robert J. ; Wood, Matthew ; Downey, Sondra L. ; Bouley, Stephanie J. ; Traphagen, Nicole A. ; Wells, Jason D. ; Batra, Jaya ; Melancon, Sir Norman ; Ringelberg, Carol ; Seibel, William ; Ratner, Nancy ; Sanchez, Nancy Yolanda. / Exploiting mitochondrial and metabolic homeostasis as a vulnerability in NF1 deficient cells. In: Oncotarget. 2018 ; Vol. 9, No. 22. pp. 15860-15875.
@article{888502f3ee5e4ee8a55dfa3e27e593a8,
title = "Exploiting mitochondrial and metabolic homeostasis as a vulnerability in NF1 deficient cells",
abstract = "Neurofibromatosis type 1 is a disease caused by mutation of neurofibromin 1 (NF1), loss of which results in hyperactive Ras signaling and a concomitant increase in cell proliferation and survival. Patients with neurofibromatosis type 1 frequently develop tumors such as plexiform neurofibromas and malignant peripheral nerve sheath tumors. Mutation of NF1 or loss of the NF1 protein is also observed in glioblastoma, lung adenocarcinoma, and ovarian cancer among other sporadic cancers. A therapy that selectively targets NF1 deficient tumors would substantially advance our ability to treat these malignancies. To address the need for these therapeutics, we developed and conducted a synthetic lethality screen to discover molecules that target yeast lacking the homolog of NF1, IRA2. One of the lead candidates that was observed to be synthetic lethal with ira2Δ yeast is Y100. Here, we describe the mechanisms by which Y100 targets ira2Δ yeast and NF1-deficient tumor cells. Y100 treatment disrupted proteostasis, metabolic homeostasis, and induced the formation of mitochondrial superoxide in NF1-deficient cancer cells. Previous studies also indicate that NF1/Ras-dysregulated tumors may be sensitive to modulators of oxidative and ER stress. We hypothesize that the use of Y100 and molecules with related mechanisms of action represent a feasible therapeutic strategy for targeting NF1 deficient cells.",
keywords = "Mitochondria, Neurofibromin 1, Proteostasis, RAS, Synthetic lethal",
author = "Allaway, {Robert J.} and Matthew Wood and Downey, {Sondra L.} and Bouley, {Stephanie J.} and Traphagen, {Nicole A.} and Wells, {Jason D.} and Jaya Batra and Melancon, {Sir Norman} and Carol Ringelberg and William Seibel and Nancy Ratner and Sanchez, {Nancy Yolanda}",
year = "2018",
month = "1",
day = "1",
doi = "10.18632/oncotarget.19335",
language = "English (US)",
volume = "9",
pages = "15860--15875",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "22",

}

TY - JOUR

T1 - Exploiting mitochondrial and metabolic homeostasis as a vulnerability in NF1 deficient cells

AU - Allaway, Robert J.

AU - Wood, Matthew

AU - Downey, Sondra L.

AU - Bouley, Stephanie J.

AU - Traphagen, Nicole A.

AU - Wells, Jason D.

AU - Batra, Jaya

AU - Melancon, Sir Norman

AU - Ringelberg, Carol

AU - Seibel, William

AU - Ratner, Nancy

AU - Sanchez, Nancy Yolanda

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Neurofibromatosis type 1 is a disease caused by mutation of neurofibromin 1 (NF1), loss of which results in hyperactive Ras signaling and a concomitant increase in cell proliferation and survival. Patients with neurofibromatosis type 1 frequently develop tumors such as plexiform neurofibromas and malignant peripheral nerve sheath tumors. Mutation of NF1 or loss of the NF1 protein is also observed in glioblastoma, lung adenocarcinoma, and ovarian cancer among other sporadic cancers. A therapy that selectively targets NF1 deficient tumors would substantially advance our ability to treat these malignancies. To address the need for these therapeutics, we developed and conducted a synthetic lethality screen to discover molecules that target yeast lacking the homolog of NF1, IRA2. One of the lead candidates that was observed to be synthetic lethal with ira2Δ yeast is Y100. Here, we describe the mechanisms by which Y100 targets ira2Δ yeast and NF1-deficient tumor cells. Y100 treatment disrupted proteostasis, metabolic homeostasis, and induced the formation of mitochondrial superoxide in NF1-deficient cancer cells. Previous studies also indicate that NF1/Ras-dysregulated tumors may be sensitive to modulators of oxidative and ER stress. We hypothesize that the use of Y100 and molecules with related mechanisms of action represent a feasible therapeutic strategy for targeting NF1 deficient cells.

AB - Neurofibromatosis type 1 is a disease caused by mutation of neurofibromin 1 (NF1), loss of which results in hyperactive Ras signaling and a concomitant increase in cell proliferation and survival. Patients with neurofibromatosis type 1 frequently develop tumors such as plexiform neurofibromas and malignant peripheral nerve sheath tumors. Mutation of NF1 or loss of the NF1 protein is also observed in glioblastoma, lung adenocarcinoma, and ovarian cancer among other sporadic cancers. A therapy that selectively targets NF1 deficient tumors would substantially advance our ability to treat these malignancies. To address the need for these therapeutics, we developed and conducted a synthetic lethality screen to discover molecules that target yeast lacking the homolog of NF1, IRA2. One of the lead candidates that was observed to be synthetic lethal with ira2Δ yeast is Y100. Here, we describe the mechanisms by which Y100 targets ira2Δ yeast and NF1-deficient tumor cells. Y100 treatment disrupted proteostasis, metabolic homeostasis, and induced the formation of mitochondrial superoxide in NF1-deficient cancer cells. Previous studies also indicate that NF1/Ras-dysregulated tumors may be sensitive to modulators of oxidative and ER stress. We hypothesize that the use of Y100 and molecules with related mechanisms of action represent a feasible therapeutic strategy for targeting NF1 deficient cells.

KW - Mitochondria

KW - Neurofibromin 1

KW - Proteostasis

KW - RAS

KW - Synthetic lethal

UR - http://www.scopus.com/inward/record.url?scp=85044374160&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85044374160&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.19335

DO - 10.18632/oncotarget.19335

M3 - Article

VL - 9

SP - 15860

EP - 15875

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 22

ER -